Impact of Reimbursement for Biomarker Testing on Clinical PracticeVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”
Grant Lawless provides an overview of the value of personalized medicine in specialty medicines and primary care settings
Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.